Deciphera Pharmaceuticals, Inc. (DCPH) Social Stream
DECIPHERA PHARMACEUTICALS INC (DCPH) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering DECIPHERA PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-08 | 10 | $64 | $10 | $23.8 | $12.11 | 96.53% |
| 2021-11-30 | 10 | $64 | $10 | $19.1 | $12.11 | 57.72% |
| 2021-12-01 | 10 | $64 | $10 | $18.1 | $12.11 | 49.46% |
| 2022-02-09 | 10 | $64 | $10 | $17.4 | $12.11 | 43.68% |
| 2022-02-10 | 10 | $64 | $8 | $17.2 | $12.11 | 42.03% |
| 2022-02-28 | 10 | $64 | $6 | $16.7 | $12.11 | 37.9% |
| 2022-04-26 | 10 | $64 | $6 | $16.8 | $12.11 | 38.73% |
| 2022-05-09 | 10 | $64 | $6 | $16.6 | $12.11 | 37.08% |
| 2022-07-27 | 9 | $64 | $6 | $18.125 | $12.11 | 49.67% |
| 2022-08-02 | 9 | $64 | $6 | $17.222 | $12.11 | 42.21% |
| 2022-08-05 | 9 | $23 | $6 | $14.666 | $12.11 | 21.11% |
| 2022-08-11 | 9 | $23 | $6 | $14.777 | $12.11 | 22.02% |
| 2022-08-30 | 10 | $25 | $6 | $15.8 | $12.11 | 30.47% |
| 2022-09-12 | 10 | $25 | $6 | $17.2 | $12.11 | 42.03% |
| 2022-11-03 | 10 | $25 | $6 | $17.9 | $12.11 | 47.81% |
| 2022-11-04 | 10 | $25 | $6 | $18.65 | $12.11 | 54% |
| 2023-01-03 | 9 | $25 | $6 | $19.388 | $12.11 | 60.1% |
| 2023-01-04 | 10 | $28 | $9 | $20.6 | $12.11 | 70.11% |
| 2023-01-18 | 10 | $28 | $9 | $21.1 | $12.11 | 74.24% |
| 2023-01-26 | 10 | $30 | $9 | $21.6 | $12.11 | 78.36% |
| 2023-02-08 | 10 | $30 | $9 | $21.5 | $12.11 | 77.54% |
| 2023-04-25 | 9 | $30 | $9 | $21.5 | $12.11 | 77.54% |
| 2023-05-04 | 9 | $30 | $9 | $21.2 | $12.11 | 75.06% |
| 2023-07-26 | 8 | $30 | $9 | $21.333 | $12.11 | 76.16% |
| 2023-10-31 | 8 | $30 | $9 | $22 | $12.11 | 81.67% |
| 2023-11-01 | 9 | $34 | $9 | $23.777 | $12.11 | 96.34% |
| 2023-11-20 | 10 | $34 | $9 | $22.8 | $12.11 | 88.27% |
The Trend in the Analyst Price Target
Over the past 32 months, DCPH's average price target has gone down $52.2.
DCPH reports an average of 54.33% for its upside potential over the past 48 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-03 | 9 | 25 | 6 | 19.388 | 15.94 | 21.63% |
| 2023-01-04 | 10 | 28 | 9 | 20.600 | 19.76 | 4.25% |
| 2023-02-08 | 10 | 30 | 9 | 21.800 | 15.72 | 38.68% |
| 2023-02-08 | 9 | 30 | 9 | 21.500 | 15.72 | 36.77% |
| 2023-08-10 | 8 | 30 | 9 | 22.000 | 15.32 | 43.6% |
DCPH Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.6 | 8 | 0 | 1 | 1 | 1 | 10 |
The Trend in the Broker Recommendations
Over the past 25 months, DCPH's average broker recommendation rating improved by 0.51.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- In terms of how DECIPHERA PHARMACEUTICALS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -2860.25% of that group.
- DECIPHERA PHARMACEUTICALS INC's average analyst price target is higher than 772.08% of all US stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, DECIPHERA PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is higher than 884.95% of them.
- In terms of how DECIPHERA PHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its number of analysts covering the stock is higher than 2192.18% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to DECIPHERA PHARMACEUTICALS INC are ZYME, AUPH, and HCM.
View All Top Stocks by Price Target
Is DCPH a Buy, Hold or Sell? See the POWR Ratings now!